Literature DB >> 29459477

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.

Vincent Yi Sheng Oei1,2, Marta Siernicka3,4, Agnieszka Graczyk-Jarzynka3, Hanna Julie Hoel1, Weiwen Yang1, Daniel Palacios1,2, Hilde Almåsbak1, Malgorzata Bajor3, Dennis Clement1,2, Ludwig Brandt5, Björn Önfelt5,6, Jodie Goodridge1,2, Magdalena Winiarska3, Radoslaw Zagozdzon3,7, Johanna Olweus1,2, Jon-Amund Kyte1,8, Karl-Johan Malmberg9,2,10.   

Abstract

Natural killer (NK) cells hold potential as a source of allogeneic cytotoxic effector cells for chimeric antigen receptor (CAR)-mediated therapies. Here, we explored the feasibility of transfecting CAR-encoding mRNA into primary NK cells and investigated how the intrinsic potential of discrete NK-cell subsets affects retargeting efficiency. After screening five second- and third-generation anti-CD19 CAR constructs with different signaling domains and spacer regions, a third-generation CAR with the CH2-domain removed was selected based on its expression and functional profiles. Kinetics experiments revealed that CAR expression was optimal after 3 days of IL15 stimulation prior to transfection, consistently achieving over 80% expression. CAR-engineered NK cells acquired increased degranulation toward CD19+ targets, and maintained their intrinsic degranulation response toward CD19- K562 cells. The response of redirected NK-cell subsets against CD19+ targets was dependent on their intrinsic thresholds for activation determined through both differentiation and education by killer cell immunoglobulin-like receptors (KIR) and/or CD94/NKG2A binding to self HLA class I and HLA-E, respectively. Redirected primary NK cells were insensitive to inhibition through NKG2A/HLA-E interactions but remained sensitive to inhibition through KIR depending on the amount of HLA class I expressed on target cells. Adaptive NK cells, expressing NKG2C, CD57, and self-HLA-specific KIR(s), displayed superior ability to kill CD19+, HLA low, or mismatched tumor cells. These findings support the feasibility of primary allogeneic NK cells for CAR engineering and highlight a need to consider NK-cell diversity when optimizing efficacy of cancer immunotherapies based on CAR-expressing NK cells. Cancer Immunol Res; 6(4); 467-80. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29459477     DOI: 10.1158/2326-6066.CIR-17-0207

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  40 in total

1.  Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.

Authors:  Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish
Journal:  Blood Adv       Date:  2020-09-08

2.  Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

Authors:  Meisam Naeimi Kararoudi; Brian P Tullius; Nitin Chakravarti; Emily J Pomeroy; Branden S Moriarity; Kathie Beland; Aurelien B L Colamartino; Elie Haddad; Yaya Chu; Mitchell S Cairo; Dean A Lee
Journal:  Semin Hematol       Date:  2020-11-19       Impact factor: 3.851

3.  CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells.

Authors:  Xiaoxuan Zhuang; Eric O Long
Journal:  Cancer Immunol Res       Date:  2019-04-24       Impact factor: 11.151

4.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

Review 5.  Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Authors:  Michelle L Saetersmoen; Quirin Hammer; Bahram Valamehr; Dan S Kaufman; Karl-Johan Malmberg
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

6.  A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers.

Authors:  Moein Dehbashi; Zohreh Hojati; Majid Motovali-Bashi; Mohamad Reza Ganjalikhany; William C Cho; Akihiro Shimosaka; Parnian Navabi; Mazdak Ganjalikhani-Hakemi
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

7.  CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.

Authors:  Arwen Stikvoort; Jort van der Schans; Subhashis Sarkar; Renée Poels; Ruud Ruiter; Jyoti Naik; Huipin Yuan; Joost D de Bruijn; Niels W C J van de Donk; Sonja Zweegman; Maria Themeli; Richard Groen; Michael O'Dwyer; Tuna Mutis
Journal:  Hemasphere       Date:  2021-06-12

Review 8.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 9.  CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

Authors:  Philipp Karschnia; Jens Blobner; Nico Teske; Florian Schöberl; Esther Fitzinger; Martin Dreyling; Joerg-Christian Tonn; Niklas Thon; Marion Subklewe; Louisa von Baumgarten
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 10.  Natural killer cells in pancreatic cancer stroma.

Authors:  Rachel Elizabeth Ann Fincham; Francesca Romana Delvecchio; Michelle R Goulart; Joe Poe Sheng Yeong; Hemant M Kocher
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.